• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Incivek - Clinical Trials - Efficacy and Side Effects by Reporting Groups - Reference Directory, Comparison Guide, Database & Handbook Product Image

Incivek - Clinical Trials - Efficacy and Side Effects by Reporting Groups - Reference Directory, Comparison Guide, Database & Handbook

  • ID: 2372973
  • January 2013
  • Region: United States
  • 37 Pages
  • PharmaFlare

Incivek - Clinical Trials - Efficacy and Side Effects by Reporting Groups - Reference Directory, Comparison Guide, Database & Handbook is a comprehensive compilation of all Incivek completed clinical trials by reporting group. The report offers comprehensive data set at the most atomic level of clinical trials & is the basis for FDA approvals & prescription choices. It also includes information and data relating to study details, phase, efficacy and safety comparison, sponsor, investigator, collaborator, and other key parameters. The report is built using data and information sourced from multiple data sources.
Scope:

- Data on the number of clinical trials conducted in the US

- Completed clinical trials data by reporting group, phase, sponsor, number of patients recruited and investigator details

- Efficacy and safety comparison by reporting groups
Who should buy this type of report?

- Pharmaceutical Companies

- Hospitals

- Insurance Companies

- Consultancies

- Universities and Research Organizations
Reasons To Buy:

- PharmaFlare’s reporting group comparison allows you to evaluate the best drug combinations within the group in terms efficacy and safety

- PharmaFlare’s color coding technique allows quick evaluation of efficacy and safety by reporting groups

- Identify and understand important clinical details of Incivek

- Reinforce R&D pipelines by identifying need gap analysis

1.1.1 List of Tables

2 Clinical Trial 1: VX-950-TiDP24-C216: A Safety and Efficacy Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
2.1 Study Details:
2.2 Efficacy and Safety Details:
2.2.1 Efficacy Reporting Groups & Description:
2.2.2 Efficacy Comparison
2.2.3 Safety Reporting Groups & Description:
2.2.4 Safety Comparison

3 Clinical Trial 2: A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C
3.1 Study Details:
3.2 Efficacy and Safety Details:
3.2.1 Reporting Groups & Description:
3.2.2 Efficacy Comparison
3.2.3 Safety Comparison:

4 Clinical Trial 3 - Phase 2 Study of VX-950, Pegasys With and Without Copegus in Hepatitis C
4.1 Study Details:
4.2 Efficacy and Safety Details
4.2.1 Efficacy Reporting Groups & Description
4.2.2 Efficacy Comparison:
4.2.3 Safety Comparison:

5 Clinical Trial 4 - Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis C
5.1 Study Details:
5.2 Efficacy & Safety Details:
5.2.1 Efficacy Reporting Groups & Description:
5.2.2 Efficacy Comparison:
5.2.3 Safety Comparison:

6 Clinical Trial 5: A Phase 3 Study of Telaprevir in Combination With Pegasys and Copegus in Treatment-Naive Subjects With Genotype 1 HCV
6.1 Study Details:
6.2 Efficacy & Safety Details:
6.2.1 Efficacy Reporting Group & Description:
6.2.2 Efficacy Comparison:
6.2.3 Safety Comparison:

7 Clinical Trial 6: A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
7.1 Study Details:
7.2 Efficacy & Safety Details:
7.2.1 Efficacy Reporting Groups & Description:
7.2.2 Efficacy Comparison:
7.2.3 Safety Comparison:

8 Clinical Trial 7: A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma HCV RNA Levels Did Not Respond to Therapy
8.1 Study Details:
8.2 Efficacy & Safety Details:
8.2.1 Efficacy Reporting Groups & Description:
8.2.2 Efficacy Comparison:
8.2.3 Safety Comparison

9 Clinical Trial 8: Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
9.1 Study Details:
9.2 Efficacy & Safety Details:
9.2.1 Efficacy Reporting Groups & Description:
9.2.2 Efficacy & Safety Comparison:

10 Clinical Trial 9: Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
10.1 Study Details:
10.2 Efficacy & Safety Details:
10.2.1 Efficacy Reporting Groups & Description:
10.2.2 Efficacy & Safety Comparison:
10.2.3 Safety Comparison:

11 Clinical Trial 10: Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
11.1 Study Details:
11.2 Safety & Efficacy Details:
11.2.1 Efficacy Reporting Groups & Description:
11.2.2 Efficacy & Safety Comparison:

12 Clinical Trial 11: Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
12.1 Study Details:
12.2 Efficacy & Safety Details:
12.2.1 Efficacy Reporting Groups & Description:
12.2.2 Efficacy & Safety Comparison:

13 Clinical Trial 12: Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
13.1 Study Details:
13.2 Safety & Efficacy Details:
13.2.1 Efficacy Reporting Groups & Description:
13.2.2 Efficacy & Safety Comparison:
13.3 About PharmaFlare
13.4 Contact Us
13.5 Disclaimer

1.1.1 List of Tables

Table 1: Clinical Trial 1 - Efficacy Comparison
Table 2: Clinical Trial 1 - Safety Comparison
Table 3: Clinical Trial 2 - Efficacy Comparison
Table 4: Clinical Trial 2- Safety Comparison
Table 5: Clinical Trial 3 - Efficacy Comparison
Table 6: Clinical Trial 3 - Safety Comparison
Table 7: Clinical Trial 4 - Efficacy Comparison
Table 8: Clinical Trial 4 - Safety Comparison
Table 9: Clinical Trial 5 - Efficacy Comparison
Table 10: Clinical Trial 5 - Safety Comparison
Table 11: Clinical Trial 6 - Efficacy Comparison
Table 12: Clinical Trial 6 - Safety Comparison
Table 13: Clinical Trial 7 - Efficacy Comparison
Table 14: Clinical Trial 7 - Safety Comparison
Table 15: Clinical Trial 8 - Safety & Efficacy Comparison
Table 16: Clinical Trial 9 - Efficacy Comparison
Table 17: Clinical Trial 9 – Safety Comparison
Table 18: Clinical Trial 10 - Safety & Efficacy Comparison
Table 19: Clinical Trial 11 - Safety & Efficacy Comparison
Table 20: Clinical Trial 12 - Safety & Efficacy Comparison

- Tibotec BVBA
- Vertex Pharmaceuticals Incorporated
- Mitsubishi Tanabe Pharma Corporation

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos